Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat in Recurrent Ovarian or Endometrial Cancer
NCT03348631Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2019
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tazemetostat in ovarian carcinoma, endometrial adenocarcinoma, sponsored by National Cancer Institute. Started May 2019; status: active, not recruiting.
02
Drugs
tazemetostat
03
Conditions
ovarian carcinomaendometrial adenocarcinoma
Beyond the preview
Go deeper on NCT03348631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03348631.